(EXEL) Exelixis - Ratings and Ratios
Cabozantinib, Cobimetinib, Zanzalintinib
EXEL EPS (Earnings per Share)
EXEL Revenue
Description: EXEL Exelixis
Exelixis Inc (NASDAQ:EXEL) is a US-based oncology company that focuses on discovering, developing, and commercializing new treatments for difficult-to-treat cancers. The company has a robust portfolio of approved medications, including CABOMETYX and COMETRIQ, which are used to treat advanced renal cell carcinoma and medullary thyroid cancer, respectively.
From a product pipeline perspective, Exelixis has a promising lineup of candidates in various stages of development, including zanzalintinib, a next-generation tyrosine kinase inhibitor, and XL309, a small molecule inhibitor of USP1. The companys research collaborations and license agreements with major pharmaceutical companies, such as Ipsen Pharma SAS and Takeda Pharmaceutical Company Ltd., demonstrate its commitment to advancing oncology research.
To evaluate Exelixis financial performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses can be analyzed. With a market capitalization of $12.43B, Exelixis has demonstrated a strong ability to generate revenue, driven by the sales of its approved medications. The companys return on equity (RoE) of 29.35% indicates a high level of profitability. Additionally, the price-to-earnings (P/E) ratio of 20.81 and forward P/E ratio of 22.42 suggest that the stock is reasonably valued relative to its earnings.
From a technical analysis perspective, Exelixis stock price has demonstrated a strong uptrend, with the 50-day simple moving average (SMA) at $42.79 and the 200-day SMA at $36.49. The current price of $44.47 is near the 52-week high of $46.26, indicating a strong bullish sentiment. The average true range (ATR) of 1.04, equivalent to 2.33%, suggests moderate volatility.
Overall, Exelixis strong product pipeline, robust financial performance, and favorable technical analysis indicators make it an attractive investment opportunity for investors looking to capitalize on the growth potential of the oncology market.
EXEL Stock Overview
| Market Cap in USD | 10,539m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2000-04-07 |
EXEL Stock Ratings
| Growth Rating | 84.7% |
| Fundamental | 93.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 20.0% |
| Analyst Rating | 3.90 of 5 |
EXEL Dividends
Currently no dividends paidEXEL Growth Ratios
| Growth Correlation 3m | -59.3% |
| Growth Correlation 12m | 82.5% |
| Growth Correlation 5y | 53.8% |
| CAGR 5y | 32.65% |
| CAGR/Max DD 3y | 1.50 |
| CAGR/Mean DD 3y | 6.15 |
| Sharpe Ratio 12m | 0.25 |
| Alpha | 0.01 |
| Beta | 0.996 |
| Volatility | 36.06% |
| Current Volume | 1718.5k |
| Average Volume 20d | 2333.9k |
| Stop Loss | 37.9 (-3.2%) |
| Signal | 0.71 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (602.3m TTM) > 0 and > 6% of Revenue (6% = 133.8m TTM) |
| FCFTA 0.28 (>2.0%) and ΔFCFTA 21.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 37.88% (prev 56.19%; Δ -18.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.29 (>3.0%) and CFO 772.0m > Net Income 602.3m (YES >=105%, WARN >=100%) |
| Net Debt (89.2m) to EBITDA (798.4m) ratio: 0.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (284.4m) change vs 12m ago -3.26% (target <= -2.0% for YES) |
| Gross Margin 96.59% (prev 96.06%; Δ 0.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 81.82% (prev 72.62%; Δ 9.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 3.34
| (A) 0.32 = (Total Current Assets 1.18b - Total Current Liabilities 336.1m) / Total Assets 2.68b |
| (B) -0.08 = Retained Earnings (Balance) -219.5m / Total Assets 2.68b |
| (C) 0.28 = EBIT TTM 768.6m / Avg Total Assets 2.73b |
| (D) -0.34 = Book Value of Equity -217.9m / Total Liabilities 644.5m |
| Total Rating: 3.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 93.69
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 7.21% = 3.60 |
| 3. FCF Margin 33.58% = 7.50 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda 0.81 = 2.01 |
| 6. ROIC - WACC (= 17.77)% = 12.50 |
| 7. RoE 27.74% = 2.31 |
| 8. Rev. Trend 82.26% = 6.17 |
| 9. EPS Trend 82.82% = 4.14 |
What is the price of EXEL shares?
Over the past week, the price has changed by +2.25%, over one month by +3.65%, over three months by -6.25% and over the past year by +42.48%.
Is Exelixis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXEL is around 40.32 USD . This means that EXEL is currently overvalued and has a potential downside of 3.01%.
Is EXEL a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.1 | 12.6% |
| Analysts Target Price | 44.1 | 12.6% |
| ValueRay Target Price | 45.3 | 15.7% |
Last update: 2025-09-16 04:34
EXEL Fundamental Data Overview
CCE Cash And Equivalents = 791.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 18.8454
P/E Forward = 14.1844
P/S = 4.7261
P/B = 5.1827
P/EG = 2.2685
Beta = 0.321
Revenue TTM = 2.23b USD
EBIT TTM = 768.6m USD
EBITDA TTM = 798.4m USD
Long Term Debt = 308.4m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 336.1m USD (from totalCurrentLiabilities, last quarter)
Debt = 644.5m USD (Calculated: Short Term 336.1m + Long Term 308.4m)
Net Debt = 89.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.39b USD (10.54b + Debt 644.5m - CCE 791.1m)
Interest Coverage Ratio = unknown (Ebit TTM 768.6m / Interest Expense TTM 0.0)
FCF Yield = 7.21% (FCF TTM 748.9m / Enterprise Value 10.39b)
FCF Margin = 33.58% (FCF TTM 748.9m / Revenue TTM 2.23b)
Net Margin = 27.01% (Net Income TTM 602.3m / Revenue TTM 2.23b)
Gross Margin = 96.59% ((Revenue TTM 2.23b - Cost of Revenue TTM 75.9m) / Revenue TTM)
Tobins Q-Ratio = -47.69 (set to none) (Enterprise Value 10.39b / Book Value Of Equity -217.9m)
Interest Expense / Debt = 4.08% (Interest Expense 26.3m / Debt 644.5m)
Taxrate = 23.53% (160.4m / 681.6m)
NOPAT = 587.7m (EBIT 768.6m * (1 - 23.53%))
Current Ratio = 3.51 (Total Current Assets 1.18b / Total Current Liabilities 336.1m)
Debt / Equity = 0.32 (Debt 644.5m / last Quarter total Stockholder Equity 2.03b)
Debt / EBITDA = 0.81 (Net Debt 89.2m / EBITDA 798.4m)
Debt / FCF = 0.86 (Debt 644.5m / FCF TTM 748.9m)
Total Stockholder Equity = 2.17b (last 4 quarters mean)
RoA = 22.49% (Net Income 602.3m, Total Assets 2.68b )
RoE = 27.74% (Net Income TTM 602.3m / Total Stockholder Equity 2.17b)
RoCE = 31.00% (Ebit 768.6m / (Equity 2.17b + L.T.Debt 308.4m))
RoIC = 27.07% (NOPAT 587.7m / Invested Capital 2.17b)
WACC = 9.30% (E(10.54b)/V(11.18b) * Re(9.68%)) + (D(644.5m)/V(11.18b) * Rd(4.08%) * (1-Tc(0.24)))
Shares Correlation 3-Years: -78.79 | Cagr: -1.21%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.41% ; FCFE base≈523.1m ; Y1≈551.0m ; Y5≈648.6m
Fair Price DCF = 31.88 (DCF Value 8.58b / Shares Outstanding 269.2m; 5y FCF grow 5.80% → 3.0% )
EPS Correlation: 82.82 | EPS CAGR: 53.70% | SUE: 0.66 | # QB: 0
Revenue Correlation: 82.26 | Revenue CAGR: 12.43% | SUE: N/A | # QB: None
Additional Sources for EXEL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle